Profile data is unavailable for this security.
About the company
Editas Medicine, Inc. is a genome-editing company developing potentially transformative genomic medicines to treat a broad range of serious diseases. It has developed a proprietary gene editing platform based on CRISPR technology that includes CRISPR/Cas9, CRISPR/Cas12a, engineered forms and foundational intellectual property for both CRISPR systems. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1), bound to a guide RNA molecule designed to recognize a particular DNA sequence. It is engaged in discovering, developing, manufacturing, and commercializing durable, precision in vivo gene-editing medicines for a broad class of diseases. Vivo medicines include vivo editing of hematopoietic stem cells (HSCs), liver cells and other tissues. Vivo gene editing in HSCs supports the advancement of research programs to treat non-malignant hematological diseases.
- Revenue in USD (TTM)46.38m
- Net income in USD-199.84m
- Incorporated2013
- Employees246.00
- LocationEditas Medicine Inc11 Hurley StCAMBRIDGE 02141-2110United StatesUSA
- Phone+1 (617) 401-9000
- Fax+1 (302) 655-5049
- Websitehttps://www.editasmedicine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rani Therapeutics Holdings Inc | 1.20m | -28.32m | 162.84m | 105.00 | -- | -- | -- | 135.70 | -0.7906 | -0.7906 | 0.0322 | -0.1093 | 0.0447 | -- | -- | 11,428.57 | -177.34 | -64.50 | -603.19 | -106.31 | -- | -- | -3,966.50 | -6,123.18 | -- | -14.32 | 8.66 | -- | -- | 0.9816 | 11.63 | -- | -29.88 | -- |
| Eledon Pharmaceuticals Inc | 0.00 | -10.27m | 165.61m | 31.00 | -- | 3.54 | -- | -- | -0.0993 | -0.0993 | 0.00 | 1.52 | 0.00 | -- | -- | 0.00 | -65.28 | -46.29 | -73.32 | -48.06 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 68.95 | -- | -- | -- |
| Cartesian Therapeutics Inc | 1.93m | -50.61m | 168.24m | 66.00 | -- | -- | -- | 87.31 | -1.97 | -1.97 | 0.0743 | -1.38 | 0.0047 | -- | 0.6943 | 29,196.97 | -11.59 | -33.50 | -12.10 | -45.25 | -- | -- | -2,489.83 | -128.46 | -- | -- | -- | -- | 49.64 | 42.27 | 69.90 | -- | 186.63 | -- |
| Century Therapeutics Inc | 113.34m | -26.48m | 168.69m | 140.00 | -- | 0.947 | -- | 1.49 | -0.3086 | -0.3086 | 1.32 | 2.04 | 0.3579 | -- | -- | 809,550.00 | -8.36 | -33.69 | -8.95 | -36.94 | -- | -- | -23.36 | -3,876.28 | -- | -- | 0.00 | -- | 194.81 | -- | 7.40 | -- | -42.55 | -- |
| Tenaya Therapeutics Inc | 0.00 | -94.26m | 168.86m | 97.00 | -- | 1.56 | -- | -- | -0.7875 | -0.7875 | 0.00 | 0.5061 | 0.00 | -- | -- | 0.00 | -76.77 | -47.44 | -87.21 | -51.82 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 10.44 | -- | -18.92 | -- |
| Zentalis Pharmaceuticals Inc | 26.87m | -149.32m | 173.40m | 166.00 | -- | 0.6857 | -- | 6.45 | -2.08 | -2.08 | 0.3743 | 3.50 | 0.0691 | -- | -- | 161,837.30 | -38.39 | -43.59 | -43.54 | -49.56 | -- | -- | -555.80 | -1,402.74 | -- | -- | 0.00 | -- | -- | -- | 43.24 | -- | -8.89 | -- |
| Editas Medicine Inc | 46.38m | -199.84m | 173.76m | 246.00 | -- | 12.34 | -- | 3.75 | -2.38 | -2.38 | 0.5454 | 0.1443 | 0.1753 | -- | 11.24 | 188,548.80 | -75.51 | -34.19 | -101.13 | -38.43 | -- | -- | -430.84 | -373.02 | -- | -- | 0.8145 | -- | -58.64 | 9.50 | -54.74 | -- | 7.43 | -- |
| Tharimmune Inc | 0.00 | -10.32m | 175.82m | 2.00 | -- | 5.46 | -- | -- | -4.11 | -4.11 | 0.00 | 0.854 | 0.00 | -- | -- | 0.00 | -159.36 | -169.40 | -225.01 | -410.04 | -- | -- | -- | -- | -- | -- | 0.0255 | -- | -- | -- | -30.89 | -- | -- | -- |
| Tiziana Life Sciences Ltd - ADR | 0.00 | -12.84m | 177.51m | 8.00 | -- | 18.21 | -- | -- | -0.1136 | -0.1136 | 0.00 | 0.0774 | 0.00 | -- | -- | 0.00 | -93.18 | -57.21 | -231.54 | -73.22 | -- | -- | -- | -- | -- | -- | 0.0115 | -- | -- | -- | 32.94 | -- | 37.77 | -- |
| Galectin Therapeutics Inc | 0.00 | -37.44m | 177.94m | 15.00 | -- | -- | -- | -- | -0.5913 | -0.5913 | 0.00 | -1.92 | 0.00 | -- | -- | 0.00 | -178.33 | -117.54 | -- | -197.34 | -- | -- | -- | -- | -- | -3.57 | -- | -- | -- | -- | -5.35 | -- | -- | -- |
| C4 Therapeutics Inc | 30.11m | -119.08m | 178.32m | 110.00 | -- | 0.8839 | -- | 5.92 | -1.67 | -1.67 | 0.4225 | 2.08 | 0.0939 | -- | 3.57 | 273,709.10 | -37.12 | -26.50 | -42.35 | -29.90 | -- | -- | -395.51 | -310.19 | -- | -- | 0.00 | -- | 71.44 | 10.72 | 20.51 | -- | -33.16 | -- |
| MDxHealth SA | 103.07m | -31.43m | 179.18m | 312.00 | -- | -- | -- | 1.74 | -0.7275 | -0.7275 | 2.21 | -0.1669 | 0.6614 | 7.00 | 6.20 | 330,349.30 | -20.17 | -40.27 | -29.24 | -50.75 | 64.48 | 57.38 | -30.50 | -76.84 | 1.02 | -0.8112 | 1.10 | -- | 28.29 | 50.19 | 11.67 | -- | 96.87 | -- |
| Sol Gel Technologies Ltd | 18.97m | -8.99m | 181.08m | 34.00 | -- | 6.96 | -- | 9.55 | -3.23 | -3.23 | 6.81 | 9.34 | 0.4891 | -- | 2.25 | 557,941.20 | -23.17 | -29.32 | -27.70 | -33.19 | -- | -- | -47.37 | -138.22 | -- | -- | 0.00 | -- | 642.47 | -12.81 | 61.16 | -- | -68.01 | -- |
| Sagimet Biosciences Inc | 0.00 | -57.67m | 183.42m | 14.00 | -- | 1.54 | -- | -- | -1.79 | -1.79 | 0.00 | 3.67 | 0.00 | -- | -- | 0.00 | -38.04 | -40.69 | -39.78 | -43.01 | -- | -- | -- | -6,987.70 | -- | -- | 0.00 | -- | -100.00 | -- | -63.46 | -- | -- | -- |
Data as of Feb 11 2026. Currency figures normalised to Editas Medicine Inc's reporting currency: US Dollar USD
27.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 7.49m | 7.67% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 6.81m | 6.98% |
| Geode Capital Management LLCas of 30 Sep 2025 | 2.04m | 2.09% |
| Teachers Advisors LLCas of 30 Sep 2025 | 1.98m | 2.03% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 1.93m | 1.97% |
| Two Sigma Investments LPas of 30 Sep 2025 | 1.58m | 1.62% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 1.28m | 1.31% |
| Two Sigma Advisers LPas of 30 Sep 2025 | 1.21m | 1.23% |
| J. Lamarck Asset Management SAas of 31 Dec 2025 | 1.12m | 1.14% |
| Bank of America, NA (Private Banking)as of 30 Sep 2025 | 1.00m | 1.03% |
More ▼
Data from 30 Sep 2025 - 30 Jan 2026Source: FactSet Research Systems Inc.
